Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase II Clinical Study to Evaluate the Efficacy and Safety of VB19055 in Participants With Hypertension (Including Resistant Hypertension) Whose Blood Pressure Remains Uncontrolled Despite Treatment With Two or More Antihypertensive Medications

NCT07833098 is registered in ClinicalTrials.gov with Zhejiang Yangli Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07833098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07833098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase II Clinical Study to Evaluate the Efficacy and Safety of VB19055 in Participants With Hypertension (Including Resistant Hypertension) Whose Blood Pressure Remains Uncontrolled Despite Treatment With Two or More Antihypertensive Medications
Lead sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
February 29, 2028
Enrollment
240 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, resistant hypertension, uncontrolled hypertension